Low-dose belantamab mafodotin (belamaf) in combination with nirogacestat vs belamaf monotherapy in patients with relapsed/refractory multiple myeloma (RRMM): phase I/II DREAMM-5 platform sub-study 3

被引：0

作者：

Leypoldt, L. ^{[1
]}

Callander, N. S. ^{[2
]}

Richardson, P. G. ^{[3
]}

Hus, M. ^{[4
]}

Ribrag, V. ^{[5
]}

Lopez, J. M. ^{[6
]}

Kim, K. ^{[7
]}

Lee, J. H. ^{[8
]}

Dimopoulos, M. A. ^{[9
,10
]}

Schjesvold, F. ^{[11
,12
]}

Facon, T. ^{[13
]}

Jo, J. -C. ^{[14
]}

Min, C. -K. ^{[15
]}

Mielnik, M. ^{[4
]}

Cheng, S. ^{[16
]}

Smith, L. M. ^{[16
]}

Breitbach, C. J. ^{[16
]}

Brawley, C. ^{[17
]}

Sembhi, H. ^{[17
]}

LaMacchia, J. ^{[18
]}

Grosicki, S. ^{[19
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[2] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Katedra & Klin Hematoonkol & Transplantacji Szpik, Lublin, Poland

[5] Inst Gustave Roussy, Villejuif, France

[6] Univ Complutense Madrid, Hosp Univ 12 Octubre, Dept Hematol, CNIO,CIBERONC, Madrid, Spain

[7] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[8] Gachon Univ, Gachon Univ Gil Med Ctr, Coll Med, Incheon, South Korea

[9] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece

[10] Alexandra Hosp, Athens, Greece

[11] Oslo Univ Hosp, Oslo Myeloma Ctr, Dept Hematol, Oslo, Norway

[12] Univ Oslo, KG Jebsen Ctr B Cell Malignancies, Oslo, Norway

[13] Lille Univ Hosp, Dept Haematol, Lille, France

[14] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Ulsan, South Korea

[15] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[16] SpringWorks Therapeut, Stamford, CT USA

[17] GSK, Stevenage, Herts, England

[18] GSK, Waltham, MA USA

[19] Med Univ Silesia, Dept Hematol & Canc Prevent, Katowice, Poland

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P330

引用

页码：176 / 177

页数：2

共 50 条

[1] Low-Dose Belantamab Mafodotin (Belamaf) in Combination With Nirogacestat Versus Belamaf Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 DREAMM-5 Platform Sub-Study 3
Callander, Natalie S.
Richardson, Paul G.
Hus, Marek
Ribrag, Vincent
Lopez, Joaquin Martinez
Kim, Kihyun
Lee, Jae Hoon
Dimopoulos, Meletis
Schjesvold, Fredrik
Facon, Thierry
Jo, Jae-Cheol
Min, Chang-Ki
Mielnik, Michal
Cheng, Shinta
Smith, L. Mary
Breitbach, Caroline J.
Brawley, Chris
Sembhi, Harjeet
LaMacchia, John
Hakim, Shawn
Kremer, Brandon E.
Grosicki, Sebastian
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S507 - S508
[2] Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Richardson, Paul G.
Nooka, Ajay
Quach, Hang
Trudel, Suzanne
Routledge, David
Song, Kevin
Nahi, Hareth
Paul, Sofia
Khan, Josephine
Brouch, Maria
Ferron-Brady, Geraldine
Yeakey, Anne
Shelton, Chris
de Oca, Rocio Montes
Smith, L. Mary
Im, Ellie
Ahlers, Christoph M.
Paul, Elaine M.
Holkova, Beata
Gupta, Ira
Kremer, Brandon E.
Rodriguez-Otero, Paula
BLOOD, 2020, 136
[3] DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM)
Richardson, Paul G.
Trudel, Suzanne
Callander, Natalie S.
Nooka, Ajay
Song, Kevin
Uttervall, Katarina
Minnema, Monique C.
Rodriguez-Otero, Paula
Struemper, Herbert
Yeakey, Anne
de Oca, Rocio Montes
Smith, L. Mary
Jackson, Nicola
Kaisermann, Morrys
Im, Ellie
Basile, Frank G.
Ahlers, Christoph M.
Holkova, Beata
Gupta, Ira
Kremer, Brandon E.
Quach, Hang
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S156 - S156
[4] Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study.
Lonial, Sagar
Grosicki, Sebastian
Hus, Marek
Song, Kevin W.
Facon, Thierry
Callander, Natalie Scott
Ribrag, Vincent
Uttervall, Katarina
Quach, Hang
Vorobyev, Vladimir I.
Min, Chang Ki
Cheng, Shinta
Smith, L. Mary
Yu, Jing
Collingwood, Therese
Holkova, Beata
Kremer, Brandon
Gupta, Ira
Richardson, Paul G.
Minnema, Monique C.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[5] DREAMM-5 platform trial: Belantamab Mafodotin (GSK2857916; belamaf; BLENREP) in combination with five different novel agents in patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Weisel, K.
Richardson, P. G.
Trudel, S.
Callander, N.
Nooka, A.
Song, K.
Uttervall, K.
Minnema, M. C.
Rodriguez-Otero, P.
Struemper, H.
Yeakey, A.
de Oca, Montes R.
Smith, L. M.
Jackson, N.
Kaisermann, M.
Im, E.
Basile, F. G.
Ahlers, C. M.
Holkova, B.
Gupta, I
Kremer, B. E.
Quach, H.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 204 - 205
[6] DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM).
Richardson, Paul G.
Biswas, Swethajit
Holkova, Beata
Jackson, Nicola
Netherway, Thelma
Paul, Sofia
Ferron-Brady, Geraldine
Yeakey, Anne
Shelton, Chris
de Oca, Rocio Montes
Ahlers, Christoph Matthias
Ballas, Marc S.
Paul, Elaine Marie
Gupta, Ira
Opalinska, Joanna
Luptakova, Katarina
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[7] DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)
Popat, Rakesh
Nooka, Ajay
Stockerl-Goldstein, Keith
Abonour, Rafat
Ramaekers, Ryan
Khot, Amit
Forbes, Adam
Lee, Cindy
Augustson, Bradley
Spencer, Andrew
Mateos, Maria-Victoria
Chopra, Bikramjit
Rogers, Rachel
Smith, Deborah A.
Davidge, Jacqueline
de Oca, Rocio Montes
Ferron-Brady, Geraldine
Yeakey, Anne
Talekar, Mala
Kremer, Brandon E.
Gupta, Ira
Quach, Hang
BLOOD, 2020, 136
[8] Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)
Popat, Rakesh
Kazantzi, Aikaterini
Farooq, Asim
Thulasi, Praneetha
Lonial, Sagar
Jakubowiak, Andrzej
Badros, Ashraf Z.
Jeng, Bennie H.
Opalinska, Joanna
Baron, January
Piontek, Trisha
Byrne, Julie
Womersley, Lynsey
Gupta, Ira
Esposti, Simona Degli
BLOOD, 2020, 136
[9] Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexamethasone (Pd) in the DREAMM-3 Study
Hungria, Vania
Weisel, Katja
Currie, Brooke
Perera, Sue
Sule, Neal
He, Wei
Davy, Katherine
McKeown, Astrid
Sapra, Sandhya
Nelsen, Linda
Li, Mary
Barale, Sophie
Boyle, Julia
McPoyle, Kaytlyn
Dimopoulos, Meletios Athanasios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S505 - S505
[10] Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)
Hungria, Vania T. M.
Weisel, Katja
Radinoff, Atanas
Delimpasi, Sosana
Mikala, Gabor
Masszi, Tamas
Li, Jian
Capra, Marcelo
Maiolino, Angelo
Pappa, Vasiliki
Chraniuk, Dominik
Osipov, Iurii
Leleu, Xavier
Low, Michael
Kouri, Fotini
Liboon, John
Brawley, Chris
Lewis, Eric
Tubel, Gabriela
Li, Mary
McKeown, Astrid
Roy-Ghanta, Sumita
Opalinska, Joanna
Dimopoulos, Meletios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S261 - S262

← 1 2 3 4 5 →